bcl-2 protein downregulation is not required for differentiation of multidrug resistant HL60 leukemia cells

M V Blagosklonny1, M Alvarez, A Fojo

  • 1Clinical Pharmacology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA.

Leukemia Research
|February 1, 1996
PubMed